Kornimate/medical-research-clean huggingface dataset:
gonadal dysgenesis tissue cryopreservation for fertility preservation

Conditions: Ovarian Cancer

Summary: the "gonadal dysgenesis tissue cryopreservation for fertility preservation" study is open to a subset of patients with disorders of sex development (dsd) which is associated with the risk of malignancy and a high risk of infertility or sterility. for these patients, experimental gonadal tissue cryopreservation is the only fertility preservation option available. the overall objective of this study is to determine the safety and efficacy of gonadal tissue cryopreservation as a method of preserving fertility and/or restoring hormonal function in patients with gonadal dysgenesis who are at risk of decreased fertility potential or malignancy.

unlike the oncology population, in which patients have inherently normal fertility potential and reproductive function, individuals with dsd may have infertility caused by 1) abnormal gonadal development, 2) gonadectomy performed for risk of malignancy, 3) abnormal hormone production or, 4) discordance, or difference, between gonadal type and gender identity. fertility potential differs according to the specific dsd diagnosis and can also be influenced by age, genetic mosaicism, and/or risk of developing a gonadal malignancy. abnormal gonadal development can result in gonadal failure, either in infancy or progressively, such that individuals may not undergo spontaneous puberty, menarche or spermarche. progressive germ cell loss may occur throughout childhood. in addition, abnormal gonadal development in certain cellular environments leads to an increased risk of germ cell cancer. traditionally, it was recommended to perform gonadectomy at the time of diagnosis in all dsd conditions with a risk of gonadal tumor formation. the estimated tumor risk ranges from 2% in complete androgen insensitivity syndrome to 40% in partial androgen insensitivity syndrome. advances in stratification of tumor risk have led to a more diagnosis-specific assessment of risk, but tumor risk remains a major concern. thus, the investigators are conducting a pilot study to assess the safety and efficacy of gonadal tissue cryopreservation as a method of preserving fertility and/or restoring hormonal function in patients with gonadal dysgenesis who are at risk of decreased fertility potential or malignancy.

Eligibility criteria:
inclusion criteria: * \< 30 years of age * individuals diagnosed with a disorder of sex development who have any risk for malignancy in their gonadal tissue and will have their gonads removed for a clinical indication * individuals diagnosed with a disorder of sex development who are at risk of primary ovarian insufficiency (poi) due to an underlying genetic condition exclusion criteria: * pregnancy * patients likely to retain inherent fertility and reproductive function * patients deemed high risk for perioperative complications * patients 7-17 years of age unable to provide assent (i.e. significant psychiatric problems/cognitive delay) * patients 18 and older unable to provide consent (i.e. significant psychiatric problems/cognitive delay)
effects of low-level laser therapy on mouth opening and surface electromyography in temporomandibular disorders

Conditions: Temporomandibular Joint Dysfunction Syndrome; Pain, Face

Summary: this is a one year followup study that aims to assess the efficacy of low level laser therapy (lllt) on pain, mouth opening and masticatory muscle activity in cases of temporomandibular dysfunction (tmd) as compared to soft occlusive splints.

a prospective, parallel randomized, controlled study will be conducted at the outpatient university clinic. participant recruitment started following approval from the ethics committee .the patients will participate in the study after signing an informed consent form prior to data collection. per inclusion criteria, subjects included are females less than 30 years of age, diagnosed with unilateral arthrogenous tmd, having complete permanent dentition and showing normal occlusion. prior to participating in any study-related procedures, participants read and signed the informed consent form approved by the institutional review board. participants will be divided into three groups; three groups: lllt (group a); soft occlusive splint therapy ost (group b); waitlist as controls (group c). outcome measures: tmj opening index (toi), vas, semg. participants were not given information on which treatment they were receiving; they were only told that they could receive one of two different treatment techniques. sessions were scheduled 3 days a week (every other day) for a total of 10 sessions

Eligibility criteria:
inclusion criteria: females less than 30 years of age, diagnosed with unilateral myogenous tmd, having complete permanent dentition showing normal occlusion exclusion criteria: prior experience of laser therapy, systemic diseases (rheumatoid arthritis, ankylosing spondylitis, diabetes... etc. history of trauma in the tmj or cervical regions; neurological disorders, muscular diseases; cervical pain; bruxism, pregnancy; currently on medication (analgesic, anti-inflammatory, muscle relaxants or anti- depressants) current use of dental prosthetics; previous orthodontal treatments; or fixed restorations affecting occlusal surfaces.

Keywords: temporomandibular dysfunction vas emg laser
the effect of allogeneic human adipose derived stem cell component extract on androgenic alopecia

Conditions: Androgenic Alopecia

Summary: this randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of the allogeneic human adipose derived stem cell component extract on androgenic alopecia in relatively healthy adults. a total of 38 subjects received 1.2 g of allogeneic human adipose derived stem cell component extract per month or a placebo for 16 weeks.

this randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of the allogeneic human adipose derived stem cell component extract on androgenic alopecia in relatively healthy adults. a total of 38 subjects received 1.2 g of allogeneic human adipose derived stem cell component extract per month or a placebo for 16 weeks. hair count and thickness will be primary outcomes.

Eligibility criteria:
inclusion criteria: * androgenic alopecia basic and specific(basp) classification: m2, c2, u1, v1, or f1 or higher exclusion criteria: * patient of scalp disease
a two-week crossover dispensing evaluation of orion daily wear soft contact lens

Conditions: Myopia

Summary: the primary objective of the study is to evaluate the clinical performance of test lens (orion) in comparison with control lens (gemini) over a period of two weeks of wear.

the primary objective of the study is to evaluate the clinical performance of test lens (orion) in comparison with control lens (gemini) over a period of two weeks of wear. this is a double-masked, randomized, bilateral, two-week crossover, dispensing study.

Eligibility criteria:
inclusion criteria: * is at least 18 years of age and has full legal capacity to volunteer. * is no greater than 55 years of age. * has read and understood the information consent letter. * is willing and able to follow instructions and maintain the appointment schedule. * is an adapted soft contact lens wearer having worn lenses for a minimum of 4 weeks prior to the study. * has spectacle cylinder ≤1.00d in both eyes. * has spherical contact lens power requirement between -1.00d and -6.00d in both eyes. * has manifest refraction visual acuities (va) equal to or better than logmar equivalent of 20/20 in each eye. * wears cls in both eyes (monovision acceptable, but not monofit) * has clear corneas and no active ocular disease. * has not worn lenses for at least 12 hours before the examination. * is willing to wear the study contact lenses for a minimum 8 hours per day/6 days per week exclusion criteria: * has never worn contact lenses before. * has any systemic disease affecting ocular health. * is using any systemic or topical medications that will affect ocular health. * has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses. * has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye. * has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars. * is aphakic. * has strabismus/amblyopia. * has undergone corneal refractive surgery. * is pregnant, lactating or planning a pregnancy. * is participating in any concurrent clinical or research study.
the detection of ctcs in patients with pancreatic cancer undergoing cryosurgery combined with dc-cik treatment.

Conditions: Neoplastic Cells, Circulating

Summary: circulating tumor cells (ctcs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. enumeration and molecular characterization of ctcs in pancreatic cancer could play an important role in diagnosis, predicting the risk for tumor recurrence, and providing novel target therapy biomarkers.in view of these facts, we wanted to demonstrate the value of multiparameter flow cytometry in detecting human tumor cells of pancreatic cancer in normal peripheral blood after cryosurgery with or without dendritic cell(dc)-cytokine-induced killers(cik) treatment, and we also compared the specificity with reverse transcriptase polymerase chain reaction (rt-pcr) method.

1 day before and 2 days after cryosurgery with or without dc-cik treatment，approximately 17-ml ethylene diamine tetraacetic acid(edta)-blood was drawn by vein puncture from patients with pancreatic cancer and healthy volunteers. the blood of the healthy volunteers will be used to evaluate the sensitivity and specificity and as negative control cells. to avoid contamination with skin cells, 2 ml blood will be discarded before the study samples will be taken.briefly, the mononucleate cells will be separated from the blood over ficoll- paque for 20 min with 1800g at 4℃. the interface cells will be removed and washed, and the red blood cells(rbcs) will be removed using a lysis buffer followed by a repeated wash. the mononuclear cells will be counted and aliquot for rt-pcr and multiparameter flow cytometry on the basis of at least 2-3×106 cells for each methodology. the cell pellet will be resuspended in phosphate-buffered saline for multiparameter flow cytometry and in trizol reagent for rt-pcr. aim : identification of ctcs may lead to better diagnosis and prognosis and could help to choose an adequate therapy.

Eligibility criteria:
inclusion criteria: 1. age:18-75 2. karnofsky performance status \>60 3. diagnosis of pancreatic cancer based on histology or the current accepted radiological measures. 4. classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ 5. will receive cryosurgery and/or dc-cik treatment 6. life expectancy: greater than 3 months 7. patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. patients with other primary tumor except pancreatic cancer 2. history of coagulation disorders or anemia

Keywords: pancreatic neoplasms circulating tumor cells
perceptions of side effects of cancer chemoradiotherapy

Conditions: Malignant Neoplasm; Side Effect

Summary: this study is asking patients who are undergoing radiation therapy with or without chemotherapy on how well they evaluate their side effects on the last day of treatment. this study is not to change health outcomes of the patients in this study. asking patients to rank side effects in order of which ones bother them the most may help researchers identify the most troubling side effects of cancer treatment.

primary objectives: i. to examine the perceptions of side effects and their subjective severity of patients treated with radiotherapy with and without concurrent chemotherapy at los angeles county (lac) + university of southern california (usc) medical center. secondary objectives: i. to identify the most troubling side effects of patients treated with radiotherapy with and without concurrent chemotherapy at lac+usc medical center. ii. to evaluate the impact of chemotherapy combined with radiation therapy, in regards to whether or not perceptions of side effects are altered by what cancer treatment is given. outline: patients are shown two groups of cards on the last day of radiation treatment. group a lists 48 physical side effects and group b lists 27 psychosocial side effects. the cards are shuffled and patients view one card at a time and select the side effects they attribute to their current treatment. patients rank the selected cards from each group by order of severity. the top 5 cards from each group are then shuffled together and patients rank the remaining 10 cards in order of severity.

Eligibility criteria:
inclusion criteria: * diagnosis of cancer * has received at least 4 consecutive weeks of definitive radiation treatment, with or without concurrent chemotherapy * has not received greater than 4 weeks of chemotherapy prior to radiation therapy start * ability to understand and the willingness to sign a written informed consent exclusion criteria: * patients with either a central nervous system (cns)-primary cancer or with brain metastases
arresting carious lesions with minimal intervention techniques

Conditions: Caries,Dental

Summary: a single-blinded randomized clinical trial with a split-mouth design that will assess the 12-month clinical and radiographic success of two minimally invasive treatment techniques, one using a chemo-mechanical caries removal agent and one using a caries arresting agent, for the treatment of deep caries in primary molars.

fifty children (100 teeth) aged 4 to 8 years with a non-contributary medical history and at least two carious primary molars (icdas 5 and 6) on different quadrants will be randomly assigned to either treatment group, using computer-generated numbers. each cavitated lesion will be isolated with cotton rolls and air-dried before being treated with one of the two types of minimal intervention technique according to the manufacturer's instructions. after the application of the agents all teeth will be restored using a high viscosity glass ionomer cement. patients will be followed clinically at 6 and 12 months and radiographically at 12 months to evaluate success of the procedures.

Eligibility criteria:
inclusion criteria: * children aged 4 to 8 years with a non-contributary medical history and sufficient compliance for the caries treatment will be included. the eligible children should have at least two carious primary molars (cavitated lesions up to 2/3 of dentin, corresponding to icdas 5 and 6) on different quadrants without any periapical pathology detected radiographically. exclusion criteria: * children aged below 4 years and above 8 years, with compromised medical history and/or allergies, with clinical or radiographic signs or symptoms of pulp pathology and with developmental dental defects will be excluded.
improvement of nutrition, digestion, and respiration in children in vietnam using oral nutritional supplementation

Conditions: Undernutrition; Wasting; Malnourished

Summary: evaluating the effect of using oral nutritional supplementation toward nutrition status, digestive disorders, upper respiratory disorders, and picky eating in children aged 24 - 59 months.

evaluating the effect of using oral nutritional supplementation toward improving the nutritional status (anthropometric index, the prevalence of malnutrition) in children aged 24 - 59 months after four months of using the nutritional product. evaluating the effect of using oral nutritional supplementation for digestive disorders (diarrhea and constipation), upper respiratory infection and picky eating in children aged 24 - 59 months. the research involves a randomized controlled clinical trial (rct), expected from 2023 to 2024 with 1000 children aged 24-59 months. the study will be conducted at schools and homes: 1000 children divided into 2 groups. one group will use the product for 4 months ( with the amount of use: twice per day, 180ml each time). the product will be distributed to the students through the schools. monitoring will be performed carefully by the commune and district health department and the centers for disease control and prevention weekly. the study aims to evaluate the effect of nutritional products toward nutritional status ( anthropometric index, the prevalence of micronutrients), digestive disorders, and picky eating in children aged 24-59 months. the nutritional product produces a high amount of energy that provides ≥ 380 kcal/360 ml; 2 bottles equal to 180ml x 2 times/day will provide 28-37,3% energy requirement for children aged 2-4 years old. the product includes fat composition which provides 38-44% energy requirement including 1899 mg medium chain triglyceride (mct), α linolenic acid, linoleic acid and 26 types of micronutrients and minerals including some essential micronutrients such as calcium 110- 130% recommended nutrition needs (rnns), iron 58-59,3% rnns, vitamin a 91-110% rnns, zinc 25-28,9% rnns, vitamin d3 54% rnns, selen 66-77,6% rnns, vitamin k1 27-31,7% rnns, folic acid 72-108% rnns. including other compositions such as 2'fl hmo (74 mg), choline (79mg), taurine (31,2mg)

Eligibility criteria:
inclusion criteria: * children between the ages of 24 and 59 months old live in 6 selected communes in yen bai province. * the family volunteered for the child to participate in the study * z-score height for age \<-1 and z-score weight for height \<1 * participated in the screening and met the selection criteria exclusion criteria: * lactose intolerance * intellectual disability or suffering from acute and chronic infectious diseases. * z-score height for age, z-score weight for height and z-score weight for age \<-4 * planing to move out of the selected trials areas in next 6 months

Keywords: picky eating children digestive condition respiratory condition wasting nutrient status
the effects of attentional filter training on working memory

Conditions: Cognitive Decline; Healthy; Age-related Cognitive Decline

Summary: the investigators are interested in how attentional filter training/ distractor inhibition training could influence cognitive functions like working memory, executive control, problem solving, decision making and attentional control.

two different computer based trainings were applied: an attentional filter training and a working memory training.

Eligibility criteria:
inclusion criteria: * right-hander * aged between 18-30 or 60-80years exclusion criteria: * severe visual impairments (e.g. dyschromatopsia, very low vision) * diseases or medication that might impair test performance * montreal cognitive assessment score (moca) \< 26 points

Keywords: training intervention filter training distractor inhibition
phase 1b/2 study of retaspimycin hcl (ipi-504) in combination with everolimus in kras mutant non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: study ipi-504-15 is a phase 1b/2 clinical trial to evaluate the safety and efficacy of retaspimycin hcl (ipi-504) plus everolimus in patients with kras mutant non-small cell lung cancer (nsclc).

this is a phase ib/2 study of retaspimycin hcl (ipi-504) in combination with everolimus. the phase 1b portion is to test the safety and tolerability of retaspimycin hcl (ipi-504) in combination with everolimus and determine the highest dose of retaspimycin hcl (ipi-504) and everolimus that can safely be given in combination. the phase 2 portion of this study will continue the evaluation of safety of retaspimycin hcl (ipi-504) in combination with everolimus and compare the effect of the study drugs on tumor response and life expectancy in patients with kras mutant nsclc.

Eligibility criteria:
inclusion criteria: 1. ≥18 years of age 2. voluntarily sign an informed consent form (icf). 3. pathological diagnosis of kras mutation positive nsclc - stage iiib or iv 4. archival nsclc tissue available to provide for analysis or have a lesion that is accessible for biopsy 5. experienced disease progression during or after receiving at least 1 prior platinum-containing chemotherapy regimen. 6. ecog performance of 0-1. exclusion criteria: 1. prior treatment with ipi-504 or other hsp90 inhibitors. 2. prior treatment with everolimus, other rapamycin analogs, ap23573(ridaforolimus), rapamycin, or other mtor inhibitors. 3. has not recovered from any toxicities related to prior treatment (to grade 1 or baseline), excluding alopecia. 4. inadequate hematologic function defined as: 5. inadequate hepatic function defined by: 6. inadequate renal function defined by serum creatinine \>1.5 x uln.

Keywords: kras mutant non-small cell lung cancer nsclc
investigating the role of atp production by airway epithelium in patients with refractory and unexplained chronic cough (rcc/ucc).

Conditions: Chronic Cough (CC)

Summary: chronic cough is a common troublesome symptom which has a global prevalence of approximately 10%, but with wide variations across continents. patients with refractory and unexplained chronic cough (rcc/ucc) often exhibit dysregulated vagal pathways, necessitating a neuronal biomarker for targeted treatment. atp, involved in the atp/p2x3 pathway, may serve as a potential biomarker due to its role in the cough reflex. the study aims to discover if atp production by the airway epithelium is greater in rcc/ucc patients compared with healthy controls, if the epithelium is a source of atp, whether gene and protein expression related to atp production differs between these groups and whether atp release is triggered by mechanical and chemical stimulation. additionally, the study seeks to determine if biomarker gene expression signatures can differentiate rcc/ucc patients from healthy controls.


Eligibility criteria:
inclusion criteria for rcc/ucc: * patients with a history of rcc/ucc. * normal chest x-ray in the last 5 years. * no evidence of airflow obstruction (fev1/fvc ratio above lln) * cough severity vas ≥ 40 mm at screening. inclusion criteria for healthy controls: * no history of chronic cough, asthma, copd, or clinical history of bronchiectasis or interstitial lung disease * no current smokers or those with \&amp;gt;10 pack year history. * no evidence of airflow obstruction ( fev1/fvc ratio above lln). * able to understand and give written informed consent. exclusion criteria: * participants who are currently established on treatment and their chronic cough is well controlled. * unable to perform acceptable and reproducible spirometry. * participants with a positive covid-19 test within 2 weeks of screening. * current smoker or ex-smoker with ≥20 pack year smoking history and abstinence of ≤6 months * symptoms of upper respiratory tract infection in the last 1 month which have not resolved * lower respiratory tract infection or pneumonia in the last 1 month * asthma exacerbation in the previous month requiring an increase or start of an inhaled corticosteroid (ics) or oral corticosteroid (ocs) * significant other primary pulmonary disorders in particular; pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, significant radiologically proven emphysema, interstitial lung disease or bronchiectasis. * history of psychiatric illness, drug or alcohol abuse which may interfere in the participation of the trial. * allergy or intolerance to sedation medication including fentanyl and midazolam, or a history of complications during procedural sedation * severe coagulopathy, bleeding disorder, or medical need for anti- coagulation that would increase the risk of endobronchial biopsy as determined by the investigator

Keywords: chronic cough atp airway nerves